Seck M, Tall A, Faye B F, Bah D Sy, Guéye Y, Sall A, Touré A O, Diop S
Service d'hématologie clinique, Université Cheikh Anta Diop, Dakar, Sénégal.
Service d'hématologie clinique, Centre national de transfusion sanguine, Dakar, Sénégal.
Med Sante Trop. 2017 Nov 1;27(4):402-406. doi: 10.1684/mst.2017.0744.
Blood transfusion is an essential therapeutic tool in the treatment of sickle cell disease. Its indications and modalities vary from one country to another as a function of the clinical severity of the disease and the availability of blood products. This study seeks to evaluate the frequency and modalities of blood transfusions as well as their indications in patients with sickle cell syndrome at the Dakar hematology department from 1995 through 2015. This retrospective study reviewed the records of a cohort of 1078 patients with SS, SC, Sβ0 and Sβ + thalassemia sickle cell syndromes and collected data about the type of blood products, indications, modalities, and acute transfusion complications. The frequency of transfusion was adjusted for age, sex, and sickle cell profile. The patients' mean age was 23 years (2-44 years) and the sex ratio 0.9. SS disease was predominant (87.4 %); 28.5% had transfusions during the study period. Patients older than 20 years received more transfusions (P = 0.047). The frequency of transfusions did not differ significantly by gender (P = 0.12), but did by profile: a higher percentage of patients with SS disease required transfusion (P = 0.043). Acute anemia was the most common indication for transfusion (50.03 %). Acute transfusion complications were rare (5.8 %). This study shows that less than one third of sickle cell anemia patients in Senegal have transfusions, a finding that confirms that our patients have fewer transfusions than patients in other countries in Africa or in the West. This limited use of transfusion therapy may be related to a less severe level of disease among patients in Senegal, but also to the availability of blood products.
输血是镰状细胞病治疗中一项重要的治疗手段。由于该病临床严重程度以及血液制品供应情况不同，其输血指征和方式在不同国家也存在差异。本研究旨在评估1995年至2015年期间达喀尔血液科镰状细胞综合征患者的输血频率、方式及其指征。这项回顾性研究查阅了1078例患有SS、SC、Sβ0和Sβ+地中海贫血镰状细胞综合征患者的病历，并收集了有关血液制品类型、指征、方式及急性输血并发症的数据。对输血频率进行了年龄、性别和镰状细胞类型的校正。患者平均年龄为23岁（2至44岁），性别比为0.9。SS病最为常见（87.4%）；28.5%的患者在研究期间接受了输血。20岁以上的患者接受输血的次数更多（P = 0.047）。输血频率在性别上无显著差异（P = 0.12），但在类型上存在差异：SS病患者需要输血的比例更高（P = 0.043）。急性贫血是最常见的输血指征（50.03%）。急性输血并发症很少见（5.8%）。本研究表明，塞内加尔不到三分之一的镰状细胞贫血患者接受输血，这一发现证实我们的患者输血次数少于非洲其他国家或西方国家的患者。输血治疗的这种有限使用可能与塞内加尔患者疾病严重程度较低有关，但也与血液制品的供应情况有关。
